← Browse by Condition
Medical Condition

graft versus host disease

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for graft versus host disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — graft versus host disease Clinical Trials

How many clinical trials are currently recruiting for graft versus host disease?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for graft versus host disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for graft versus host disease?
graft versus host disease research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a graft versus host disease clinical trial?
Eligibility criteria for graft versus host disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 3
2
Top Sponsors
Memorial Sloan Kettering Cancer Center 1 trial
Christopher Dvorak 1 trial
Nantes University Hospital 1 trial
Washington University School of Medicine 1 trial
Shanghai Jiao Tong University School of Medicine 1 trial

Recruiting Clinical Trials

NCT07006506 Phase 2
Recruiting
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Enrollment
46 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT04337515
Recruiting
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Enrollment
90 pts
Location
United States
Sponsor
Christopher Dvorak
View Trial →
NCT06252870 Phase 2
Recruiting
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Enrollment
82 pts
Location
France
Sponsor
Nantes University Hospital
View Trial →
NCT06008808 Phase 1
Recruiting
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment
41 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT06705062 Phase 3
Recruiting
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
Enrollment
316 pts
Location
China
Sponsor
Shanghai Jiao Tong University ...
View Trial →
NCT06682169 Phase 3
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Enrollment
182 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic...
View Trial →

Related Conditions

graft vs host disease (3) hematologic malignancy (2) allogeneic hematopoietic cell transplant (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology